SJCRH 
9/90, 2/91 
NEBREL 
A PHASE II TRIAL OF HIGH-DOSE CARBOPLATIN AND ETOPOSIDE WITH 
AUTOLOGOUS MARROW SUPPORT FOR TREATMENT OF 
RELAPSE/REFRACTORY NEUROBLASTOMA WITHOUT 
APPARENT BONE MARROW INVOLVEMENT: 
USE OF MARKER GENES TO INVESTIGATE THE BIOLOGY OF 
MARROW RECONSTITUTION AND THE MECHANISM OF RELAPSE 
PRINCIPAL INVESTIGATORS 
Victor M. Santana, M.D. 
Malcolm K Brenner, MA, PhD, FRCP, MRCPath 
Joseph Mirro, Jr., M.D. 
James Ihle, Ph.D. 
Co-Investigators 
Raul Ribeiro, M.D. 
Craig Hurwitz, M.D. 
Hazem Mahmoud, M.D. 
Katy Garth, R.N., M.S.N., C.F.N.P. 
Robert C. Moen, M.D., G.T.I. 
W. French-Anderson, M.D., N.I.H. 
St. Jude Children’s Research Hospital 
Memphis, Tennessee 38101 
[708] 
Recombinant DNA Research, Volume 14 
